Insignificant effects of loss of heterozygosity in HLA in the efficacy of immune checkpoint blockade treatment

3Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: It is assumed that loss of heterozygosity and allelic copy loss in HLA gene is associated with poor response rates in immune checkpoint inhibitor treatment. H-owever, the accurate extents or consistency in cancer types have not been explored. Objective: The goal of this study is to investigate quantitative relationship between HLA allelic copy loss and response rates to immune checkpoint inhibitors. Also, tumor microenvironment was computationally assessed in the tumors with HLA copy loss to provide potential mechanisms for the relationships. Method: A total of 282 whole exome sequencing data from three cohorts of patients who received immune checkpoint blockade immunotherapy were analyzed, including Anti-PDL1 treated in metastatic urothelial cancer (N = 216), anti-PD1 treated metastatic melanoma (N = 26), and anti-CTLA4 treated metastatic melanoma (N = 39). The LOHHLA algorithm was used to calculate allelic copy number loss at each HLA-A, -B, and -C locus, and further determine HLA allelic copy loss status. The HLA copy status and ICB response rates were analyzed for association using Fisher’s exact test. The CIBERSORT-absolute algorithm was then used to analyze the patient's immune environment, which represented loss of heterozygosity, using paired matched RNA sequencing data. Results: Unlike the general expectation, HLA allelic copy loss was not significantly associated with the ICB responses. Moreover, the relationship showed a reversed relationship in HLA-A in the urothelial cancer (better ICB response in HLA copy loss). Regardless of the HLA copy status, the proportion of cytotoxic immune cells in the immune environment of patients was correlated with ICB response, which was higher in the loss of heterozygosity group in the urothelial cohort. Conclusion: Although the loss of heterozygosity in HLA was generally expected to be an inhibitory factor in the immune treatment response by causing T cell immune evasion, our analysis demonstrates no explicit relationships.

References Powered by Scopus

STAR: Ultrafast universal RNA-seq aligner

29765Citations
N/AReaders
Get full text

RSEM: Accurate transcript quantification from RNA-Seq data with or without a reference genome

15088Citations
N/AReaders
Get full text

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

3521Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti-PD-1 Monotherapy: A Report from the International RRD Consortium

18Citations
N/AReaders
Get full text

A pan-cancer single-cell RNA-seq atlas of intratumoral B cells

6Citations
N/AReaders
Get full text

Loss of Human Leukocyte Antigen and Immune Escape in Head and Neck Cancer

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Yang, Y., Kim, E., & Kim, S. (2022). Insignificant effects of loss of heterozygosity in HLA in the efficacy of immune checkpoint blockade treatment. Genes and Genomics, 44(4), 509–515. https://doi.org/10.1007/s13258-021-01207-8

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 3

60%

Lecturer / Post doc 1

20%

Researcher 1

20%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 3

60%

Nursing and Health Professions 1

20%

Immunology and Microbiology 1

20%

Save time finding and organizing research with Mendeley

Sign up for free